In recent years, molecular testing in the medical world has exploded in popularity,
mainly due to advances in the diagnosis and treatment of cancer and the pursuit of
individualized medicine. Meanwhile, non-neoplastic fields seem to have lagged behind
when it comes to harnessing the power of the genome at the bedside. This may be because
the molecular landscape of non-neoplastic disease is often highly complex, with increased
influence of environmental factors and frequent involvement of multiple genes. However,
the importance of genetic changes in these fields is becoming more and more evident,
leading to new insights into disease pathogenesis, improved prognostication, and promising
new therapies.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The genetics of cardiovascular disease: new insights from emerging approaches.J Pathol. 2010; 220: 186-197
- Genetics of human cardiovascular disease.Cell. 2012; 148: 1242-1257
- Internalization-defective LDL receptors produced by genes with nonsense and frameshift mutations that truncate the cytoplasmic domain.Cell. 1985; 41: 735-743
- Family history as an independent risk factor for coronary artery disease.J Am Coll Cardiol. 1984; 4: 793-801
- Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy.N Engl J Med. 1995; 332: 1058-1064
- The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms.Cell. 2001; 104: 557-567
- Adult congenital heart disease in a nationwide population 2000-2014: epidemiological trends, arrhythmia, and standardized mortality ratio.J Am Heart Assoc. 2018; 7
- Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study.Circulation. 2010; 122: 868-875
- Long-term outcomes of tetralogy of Fallot: a study from the Pediatric Cardiac Care Consortium.JAMA Cardiol. 2019; 4: 34-41
- Familial tetralogy of Fallot caused by mutation in the jagged1 gene.Hum Mol Genet. 2001; 10: 163-169
- Mutations in NOTCH1 cause aortic valve disease.Nature. 2005; 437: 270-274
- GATA4 sequence variants in patients with congenital heart disease.J Med Genet. 2007; 44: 779-783
- Congenital heart disease caused by mutations in the transcription factor NKX2-5.Science. 1998; 281: 108-111
- Genetic heterogeneity and phenotypic anomalies in children with atrioventricular canal defect and tetralogy of Fallot.Clin Dysmorphol. 2006; 15: 65-70
- 22q11.2 deletion syndrome is associated with increased mortality in adults with tetralogy of Fallot and pulmonary atresia with ventricular septal defect.Int J Cardiol. 2020; 306: 56-60
- Impact of a 22q11.2 microdeletion on adult all-cause mortality in tetralogy of Fallot.Can J Cardiol. 2020; 36: 1091-1097
- 22q11.2 deletions in patients with conotruncal defects: data from 1,610 consecutive cases.Pediatr Cardiol. 2013; 34: 1687-1694
- All-cause mortality and survival in adults with 22q11.2 deletion syndrome.Genet Med. 2019; 21: 2328-2335
- Deletion of chromosome 22q11.2 and outcome in patients with pulmonary atresia and ventricular septal defect.Ann Thorac Surg. 2003; 76: 567-571
- 22q11.2 deletion syndrome and congenital heart disease.Am J Med Genet C Semin Med Genet. 2020; 184: 64-72
- The impact of 22q11.2 deletion syndrome on surgical repair outcomes of conotruncal cardiac anomalies.Ann Thorac Surg. 2017; 104: 1597-1604
- HER2-positive breast cancer.Lancet. 2017; 389: 2415-2429
- Gene therapy strategies in the treatment of hypertrophic cardiomyopathy.Pflugers Arch. 2019; 471: 807-815
- Novel therapies for prevention and early treatment of cardiomyopathies.Circ Res. 2019; 124: 1536-1550
- Next-generation sequencing to identify genetic causes of cardiomyopathies.Curr Opin Cardiol. 2012; 27: 214-220
Article info
Publication history
Published online: May 16, 2020
Accepted:
May 10,
2020
Received:
May 8,
2020
Footnotes
See article by van Mil et al., pages 1091–1097 of this issue.
See page 998 for disclosure information.
Identification
Copyright
© 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Impact of a 22q11.2 Microdeletion on Adult All-Cause Mortality in Tetralogy of Fallot PatientsCanadian Journal of CardiologyVol. 36Issue 7
- PreviewBecause of the importance of identifying factors that affect late outcomes in the increasing population of those with tetralogy of Fallot (TOF), we aimed to determine the effect of a 22q11.2 microdeletion on adult mortality, while accounting for pulmonary atresia, known to be enriched in 22q11.2 deletion syndrome (22q11.2DS).
- Full-Text
- Preview
